Scott Isaacs, MD, Endocrinologist and Weight Loss Specialist

08/14/2025

The symptoms of thyroid disease and menopause can overlap, making diagnosis a challenge.
https://health.yahoo.com/your-body/womens-health/menopause/article/menopause-or-thyroid-192720088.html

07/18/2025

Tirzepatide improves metabolic hypogonadism better than transdermal testosterone according to this study presented at . Always happy to give my comments for MedCentral.
https://www.medcentral.com/endocrinology/hormones/tirzepatide-shown-to-tackle-hypogonadism

07/14/2025

It was a privilege to help Andrea Petersen as she explored her journey with continuous glucose monitoring for The Wall Street Journal. Fluctuations in glucose levels are a normal part life, and using a can provide meaningful insights into how the foods you eat impact your body. American Association of Clinical Endocrinology
https://www.wsj.com/health/wellness/zoe-gut-health-test-9d950f8f?st=2yYH3c&reflink=desktopwebshare_permalink

06/11/2025

New research links GLP-1 meds to a 2-fold higher risk of wet age-related macular degeneration in people with type 2 diabetes. While the absolute risk remains low, risk increases with longer use and in older adults. Honored to contribute to this important discussion with Health.

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease that can cause blindness. But researchers stress that more research is needed to understand this relationship.

06/09/2025

I’m delighted to present the June American Association of Clinical Endocrinology President’s Update, which highlights the inspiring connections made at our 2025 Annual Meeting in Orlando.

AACE President Scott D. Isaacs, MD, FACP, FACE, shares highlights from the 2025 Annual Meeting, including advances in endocrine care, renewed collaboration with local organizations, and the approval of AACE’s strategic plan for 2026 and beyond.

06/06/2025

Honored to moderate a session on multidisciplinary teams in .

05/07/2025

I’m honored to be quoted in this article about the surprising effects of rapid weight loss from GLP medications like Ozempic. Changes can appear as “Ozempic face,” “Ozempic butt,” “Ozempic feet,” “Ozempic hands,” and even “Ozempic fingers” due to fat loss outpacing skin’s ability to adjust. Slower weight loss, staying hydrated, and supportive shoes can help.
https://www.health.com/what-are-ozempic-feet-11722358

04/28/2025

Had a fantastic time joining The Curbsiders to talk all about Prediabetes and Diabetes Prevention. Huge thanks to Dr. Matt Watto and Dr. Paul Williams for their thoughtful questions, and to producer Dr. Malini Gupta for her expert touch. Honored to be part of the #1 internal medicine podcast with such outstanding hosts!

Conquer prediabetes and diabetes prevention! We’re joined by Dr. Scott Isaacs, who provides essential pearls on navigating screening tests for diabetes and ...

04/25/2025

What an incredible honor to speak on MASLD at the Obesity Medicine Association conference in National Harbor, Maryland. Grateful for the opportunity to share and learn alongside so many dedicated leaders in obesity medicine!

04/13/2025

Cover Article BMJ Frontline Gastroenterology: Role of anti-diabetic medications in the management of MASLD. This review provides a comprehensive analysis of the effects of the entire spectrum of diabetes medications on MASLD, including pioglitazone, GLP-1 receptor agonists, SGLT2 inhibitors, metformin, DPP4 inhibitors, sulfonylureas and insulin. We are so honored that this article has received so much attention. Huge thanks to my coauthors Fiona Farrelly and Paul Brennan, and to our editor Oliver Tavabie.
https://fg.bmj.com/content/16/3/239.full?ijkey=VFtd4ASzBGJhxfK&keytype=ref

04/05/2025

I am honored to attend the American College of Physicians (ACP) meeting as an invited guest. I have enjoyed meeting inspiring leaders. I am proud to represent American Association of Clinical Endocrinology.

03/07/2025

Eli Lilly has reduced the prices of vials and introduced higher-dose options, making more accessible. I am honored to give my perspective on behalf of American Association of Clinical Endocrinology for Health.

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug more accessible for some patients.